Novartis dumps worldwide rights to an Aveo drug, and the little biotech is not happy with them
Three years after Novartis stepped up and chipped in a $15 million upfront in a $326 million deal to partner with Aveo $AVEO on their …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
